Platelet activation in acute myocardial infarction and the rationale for combination therapy

Ian Conde-Pozzi, Neal Kleiman

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Current fibrinolytic regimens fail to fully restore coronary blood flow in slightly less than 50% of patients with acute myocardial infarction. Platelet activation and aggregation may be responsible for a large proportion of these therapeutic failures. Therefore, platelet inhibition may enhance thrombolysis. Experimental and early clinical evidence suggest that glycoprotein IIb/IIIa antagonists may enhance reperfusion when combined with reduced doses of thrombolytic agents. However, the clinical benefit of combination therapy will depend on the outcomes of a number large clinical trials that are currently being performed.

Original languageEnglish (US)
Pages (from-to)378-385
Number of pages8
JournalCurrent Cardiology Reports
Volume2
Issue number5
DOIs
StatePublished - Dec 1 2000

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Platelet activation in acute myocardial infarction and the rationale for combination therapy'. Together they form a unique fingerprint.

Cite this